Acthar®

Status
To Patients
Condition
Sarcoidosis ILD
Intervention Type
Subcutaneous (SC) Injection
Funder Type
Industry

Drug Details

Acthar® Gel (repository corticotropin injection) is FDA approved for the treatment of people with symptoms of sarcoidosis.

Study Purpose

The purpose of this study is to evaluate the efficacy and safety of H.P. Acthar® Gel (Acthar) in the treatment of pulmonary sarcoidosis.

Find a Clinical Trial
footer_txt_bblBook a PFF Ambassador for your event.   Call 844.TalkPFF >